Archive: Company News
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
– Novel compound for targeted tumor therapy to be evaluated in patients with soft tissue sarcoma
– First patients to be enrolled in Q2, 2023
Thermosome, a drug development company specializing in targeted tumor therapies, today announced that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible Ethics Committee to conduct a Phase 1 trial with its lead program THE001 in Germany. Patient enrollment is expected to start in Q2, 2023.
The primary endpoints of the Phase 1, open-label, interventional dose-escalation study are the safety and tolerability of THE001 and the determination of the maximum tolerated dose. A secondary objective is to evaluate anti-tumor activity. Read more…
HpVac reports positive effects of its lead compound HpVac-R13 in a murine model of allergic asthma following oral administration
– Study results indicate beneficial effects on airway hyperresponsiveness, remodeling and inflammation
HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced positive results of its lead compound HpVac-R13 on airway hyperresponsiveness and inflammation in a murine model of allergic asthma.
Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
– Leading translational medicine and neuroscience expert to head Dopavision’s research activities
Dopavision, a clinical-stage company pioneering the development of digitally delivered light-based therapeutics, today announced the appointment of Prof. Dr. Jens Ellrich as Chief Scientific Officer. Jens Ellrich brings a wealth of scientific knowledge and extensive experience in digital therapeutics, including new product development. He will spearhead Dopavision’s ambitious research and development activities for the Company’s lead product, MyopiaX®, Dopavision’s leading-edge digital therapeutic for childhood myopia control. The first-in-human clinical investigation of MyopiaX® is ongoing across Europe.
Cellbox Solutions Raises EUR 6.5 Million in Series A1 Financing Round
– CK Ventures, Fraunhofer Ventures, NRW.Venture and Fil Bros join forces with renowned private investors
– Planned expansion of US business and launch of tailored cell therapy shipment solutions
Cellbox Solutions GmbH, a healthcare company providing live cell logistics solutions for research, development and shipment of life-sustaining therapies, today announced the closing of a Series A1 financing round totaling EUR 6.5 million. The round was led by CK Ventures, supported by Fraunhofer Ventures and several new investors such as NRW.Venture, Fil Bros, and experienced private investors. Representatives of the new investors will take an active role on the board of the company and will be announced separately.